#### Archives of Biochemistry and Biophysics 601 (2016) 113-120



Contents lists available at ScienceDirect

### Archives of Biochemistry and Biophysics

journal homepage: www.elsevier.com/locate/yabbi



CrossMark

## Mutations in troponin T associated with Hypertrophic Cardiomyopathy increase Ca<sup>2+</sup>-sensitivity and suppress the modulation of Ca<sup>2+</sup>-sensitivity by troponin I phosphorylation\*

Andrew E. Messer <sup>a, \*</sup>, Christopher R. Bayliss <sup>a</sup>, Mohammed El-Mezgueldi <sup>b</sup>, Charles S. Redwood <sup>c</sup>, Douglas G. Ward <sup>d</sup>, Man-Ching Leung <sup>a</sup>, Maria Papadaki <sup>a</sup>, Cristobal dos Remedios <sup>e</sup>, Steven B. Marston <sup>a</sup>

<sup>a</sup> Imperial College London, London, UK

<sup>b</sup> University of Leicester, Leicester, UK

<sup>c</sup> University of Oxford, Oxford, UK

<sup>d</sup> University of Birmingham, Birmingham, UK

<sup>e</sup> University of Sydney, Sydney, Australia

#### ARTICLE INFO

Article history: Received 3 November 2015 Received in revised form 16 March 2016 Accepted 26 March 2016 Available online 29 March 2016

Keywords: Hypertrophic Cardiomyopathy Troponin T Phosphorylation of troponin I Ca<sup>2+</sup> regulation of contractility In vitro motility assay

#### ABSTRACT

We investigated the effect of 7 Hypertrophic Cardiomyopathy (HCM)-causing mutations in troponin T (TnT) on troponin function in thin filaments reconstituted with actin and human cardiac tropomyosin. We used the quantitative *in vitro* motility assay to study Ca<sup>2+</sup>-regulation of unloaded movement and its modulation by troponin I phosphorylation. Troponin from a patient with the K280N TnT mutation showed no difference in Ca<sup>2+</sup>-sensitivity when compared with donor heart troponin and the Ca<sup>2+</sup>-sensitivity was also independent of the troponin I phosphorylation level (uncoupled). The recombinant K280N TnT mutation increased Ca<sup>2+</sup>-sensitivity 1.7-fold and was also uncoupled. The R92Q TnT mutation in troponin from transgenic mouse increased Ca<sup>2+</sup>-sensitivity and was also completely uncoupled. Five TnT mutations ( $\Delta$ 14,  $\Delta$ 28 + 7,  $\Delta$ E160, S179F and K273E) studied in recombinant troponin increased Ca<sup>2+</sup>-sensitivity and was also completely uncoupled. Five TnT mutations in *trito* is the usual response and both factors may contribute to the HCM phenotype. We also found that Epigallocatechin-3-gallate (EGCG) can restore coupling to all uncoupled HCM-causing TnT mutations. In fact the combination of Ca<sup>2+</sup>-desensitisation and re-coupling due to EGCG completely reverses both the abnormalities found in troponin with a TnT HCM mutation suggesting it may have therapeutic potential.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

#### 1. Introduction

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and is usually associated with mutations

\* Corresponding author. National Heart and Lung Institute, Imperial College London, Myocardial Function, Imperial Centre for Translational and Experimental Medicine, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK.

E-mail address: a.messer@imperial.ac.uk (A.E. Messer).

in sarcomeric proteins. A recent study has shown that 11% of the identified mutations are in the proteins of the thin filament; actin, tropomyosin, troponin I (TnI), troponin C (TnC) and troponin T (TnT) [1]. It is generally found that HCM-causing mutations result in a 2–3 fold higher myofilament  $Ca^{2+}$ -sensitivity compared to normal heart muscle and this has been proposed to be necessary to trigger the symptoms of HCM: a hyper-contractile phenotype, heart muscle hypertrophy, myocyte disarray and fibrosis [2], although the clinical manifestation of HCM is very variable, probably due to background genetic and environmental factors.

Mutations in the same sarcomeric protein genes are also associated with familial dilated cardiomyopathy (DCM), a disease characterised by a hypo-contractile phenotype with dilation of the heart chamber and thinning of cardiac muscle [3]. Whilst DCM clearly has a

http://dx.doi.org/10.1016/j.abb.2016.03.027

0003-9861/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Abbreviations: DCM, Dilated Cardiomyopathy; EGCG, Epigallocatechin-3-Gallate; HCM, Hypertrophic Cardiomyopathy; IVMA, *In vitro* Motility Assay; k<sub>ACT</sub>, Rate of force development; k<sub>REL</sub>, Rate of fast relaxation phase; n<sub>H</sub>, Hill Coefficient; TnC, Troponin C; Tnl, Troponin I; TnT, Troponin T; WT, wild-type.

<sup>\*</sup> This article is part of a Special Issue entitled Myofilament Modulation of Cardiac Contraction, edited by Brandon J. Biesiadecki.

#### Table 1

Effect of the HCM related TnT K280N mutation on  $Ca^{2+}$ -sensitivity and phosphorylation dependence of  $Ca^{2+}$ -sensitivity using the TnT K280N patient sample (see Fig. 1). X = exchanged. All data rounded to 2 significant figures.

	Experiment	EC <sub>50</sub> , μM		Ratio (EC <sub>50</sub> Test/Control)	Control) n		TnI Phosphorylation	
	Test vs Control	Test	Control				Test	Control
Α	Donor vs K280N patient	0.19 ± 0.015	0.20 ± 0.016	×0.99 ± 0.047	11	0.87	$1.6 \pm 0.060$	$1.4 \pm 0.020$
В	K280N vs dpK280N patient	$0.14 \pm 0.022$	$0.14 \pm 0.024$	$\times 0.99 \pm 0.020$	6	0.54	$1.4 \pm 0.090$	$0.11 \pm 0.10$
С	Donor vs dpDonor	$0.14 \pm 0.030$	$0.050 \pm 0.010$	$\times 3.1 \pm 0.55$	10	0.0040	$1.6 \pm 0.070$	$0.23 \pm 0.070$
D	K280N patientXTnT vs dpK280N patientXTnT	$0.16\pm0.035$	0.088 ± 0.013	$\times 1.8 \pm 0.17$	4	0.022	$1.4 \pm 0.12$	$0.090\pm0.070$

separate molecular mechanism from HCM, the simple hypothesis that  $Ca^{2+}$ -sensitivity is reduced in familial DCM (the opposite of HCM) has proven to be incorrect since changes of  $Ca^{2+}$ -sensitivity do not correlate with the phenotype [2,4,5]. Our investigations have established that a consistent feature of DCM-causing mutations in thin filament proteins is that the  $Ca^{2+}$ -sensitivity is not modulated by

ThI phosphorylation, a process we have called uncoupling, and we have proposed that this is a disease-mechanism [4-6].

TnI is one of several substrates of protein kinase A (PKA). In normal heart, on adrenergic stimulation PKA is activated and TnI phosphorylation at Ser22 and 23 is increased. Phosphorylation of TnI decreases myofibrillar Ca<sup>2+</sup>-sensitivity 2–3 fold and



**Fig. 1. Effect of the HCM related TnT K280N mutation (patient sample)**. The fraction of filaments motile, measured in a paired experiment by IVMA, is plotted against  $[Ca^{2+}]$  for representative single experiments. The mean values of  $EC_{50}$  from replicate experiments are shown in Table 1. Solid lines and points, phosphorylated troponin; dotted lines and open points, unphosphorylated troponin. Error bars represent SEM of four measurements of motility in the same motility chamber. Blue, native donor thin filaments; red, TnT K280N patient thin filaments; green, WT TnT exchanged into TnT K280N patient thin filaments. A. Donor and TnT K280N patient containing thin filaments: no change in  $EC_{50}$  ( $Ca^{2+}$ -sensitivity) was seen. B. Effect of phosphorylation on thin filaments containing the TnT K280N mutation. The relationship of  $Ca^{2+}$ -sensitivity to TnI phosphorylation is uncoupled. C. Effect of phosphorylation on onor thin filaments. Normal relationship as phosphorylation increased  $EC_{50}$ . D. The difference in  $Ca^{2+}$ -sensitivity is restored when recombinant human cardiac TnT was exchanged into native TnT K280N patient thin filaments.

Download English Version:

# https://daneshyari.com/en/article/8289325

Download Persian Version:

https://daneshyari.com/article/8289325

Daneshyari.com